West Orange, NJ, United States of America

Panayiotis Stevis

This inventor holds 19 USPTO granted patents and 5 published patent applications, plus 2 CIPO patents and 6 EPO patents, primarily in Leptin Receptor Modulation. Top assignees: Regeneron Pharmaceuticals, Inc., Regeneran Pharmaceuticals, Inc.. Active years: 2016-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Panayiotis Stevis. Retrieved from https://idiyas.com/inventor/panayiotis-stevis

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 19 (Patent Applications = 5)

% Patents Active = 94.7

CIPO Patents = 2 (Patent Applications = 5)

EPO Patents = 6 (Patent Applications = 9)

Average Co-Inventor Count = 3.6

ph-index = 5

Forward Citations = 65(Granted Patents)

Location History:

West Orange, NY (US) (2017)
Tarrytown, NY (US) (2022)
West Orange, NJ (US) (2016 - 2023)

Company Filing History:

18 out of 1,482

Regeneron Pharmaceuticals, Inc.

patents

1 out of 49

Regeneran Pharmaceuticals, Inc.

patents

Years Active: 2016-2026

Loading Chart...

Areas of Expertise:

Monospecific Antibodies

Leptin Receptor

Antigen-Binding Proteins

Bispecific Molecules

Fusion Proteins

APLNR

Cardiac Function

Pathological Angiogenesis

HSD17B Family

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12715927 - MONOSPECIFIC ANTIBODIES THAT ANTAGONIZE LEPTIN RECEPTOR (2026-08-25),

2. 12371503 - Methods of treatment using a leptin receptor agonist antibody (2025-07-29),

3. 12275792 - Antigen-binding proteins that activate the leptin receptor (2025-04-14),

4. 11834500 - Bispecific antigen binding molecules that bind leptin receptor and/or GP130, and methods of use thereof (2023-12-05),

5. 11642390 - Method of treatment with a fusion protein comprising apelin and an anti-APLNR antibody (2023-05-09),

6. 11608381 - Methods of treatment using a leptin receptor agonist antibody (2023-03-21),

7. 11535675 - Antigen-binding proteins that antagonize leptin receptor (2022-12-27),

8. 11479802 - Assays for screening activity of modulators of members of the hydroxy steroid (17-beta) dehydrogenase (HSD17B) family (2022-10-25),

9. 10947310 - Fusion protein comprising apelin and an anti-APLNR antibody (2021-03-16),

10. 10626173 - Method for treating pathological angiogenesis by administering an antibody that inhibits APLNR (2020-04-21),

11. 10618968 - Antigen-binding proteins that activate the leptin receptor (2020-04-14),

12. 10550192 - Antigen-binding proteins that antagonize leptin receptor (2020-02-04),

13. 10253102 - Antigen-binding proteins that activate the leptin receptor (2019-04-09),

14. 10189901 - Methods for improving cardiac function by administering an antibody that activates APLNR (2019-01-29),

15. 10155811 - APLNR modulators and uses thereof (2018-12-18),

Title: The Innovative Journey of Panayiotis Stevis

Introduction: Panayiotis Stevis, a talented inventor hailing from West Orange, NJ, has made significant contributions to the field of technology with his groundbreaking innovations.

Latest Patents: Panayiotis Stevis holds several patents in the realm of artificial intelligence and renewable energy technologies, showcasing his commitment to creating a sustainable future.

Career Highlights: With a background in engineering and a passion for problem-solving, Panayiotis Stevis has led numerous successful projects that have revolutionized industries such as robotics, healthcare, and environmental conservation.

Collaborations: Throughout his career, Panayiotis Stevis has collaborated with leading research institutions, universities, and tech companies to bring his ideas to life. His ability to work in multidisciplinary teams has resulted in the development of cutting-edge technologies.

Conclusion: Panayiotis Stevis continues to push the boundaries of innovation, inspiring the next generation of inventors to think outside the box and create solutions that have a lasting impact on society.

Profile summary based on public USPTO records.